| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Customized |
|
Still deciding? Get samples of $ !
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | Betahistine Dihydrochloride |
| Appearance | White to almost crystalline powder, very hygroscopic |
| Assay | 99.0%~101.0% |
| pH | 2~3 |
| Loss on drying | ≤1.0% |
| Sulphated ash | ≤0.1% |
| Identification | IR: Similar to the reference standard HPLC: Similar to the reference standard |
| Residual solvents(2-p-ropanol) | ≤0.5% |
| Solubility | Very soluble in water Freely soluble in alcohol (96%) Practically insoluble in 2-p-ropanol |
| Clarity of solution | (0.1g in10ml carbon dioxide free water)-clear |
| 2-(2-Hydroxyethyl) p-yridine | ≤0.2% |
| 2-Vinylp-yridine | ≤0.2% |
| N-Methyl-N,N-bis(2-Pyridin-2-yl-ethyl)amine | ≤0.2% |
| Other individual impurity | ≤0.1% |
| Total impurities | ≤0.5% |
Betahistine dihydrochloride is a histamine H3 receptors inhibitor used as an antivertigo drug. Target: Histamine Receptor Betahistine dihydrochloride, a structural analogue of histamine with weak histamine H(1) receptor agonist and more potent H(3) receptor antagonist properties. Betahistine dihydrochloride acts centrally by enhancing histamine synthesis within tuberomammillary nuclei of the posterior hypothalamus and histamine release within vestibular nuclei through antagonism of H(3) autoreceptors [1]. Therapeutic effects of betahistine in vestibular disorders result from its antagonist properties at histamine H(3) receptors (H(3)Rs). On inhibition of cAMP formation and [(3)H]arachidonic acid release, betahistine behaved as a nanomolar inverse agonist and a micromolar agonist. After acute oral administration, Betahistine increased t-MeHA levels with an ED(50) of 2 mg/kg, a rightward shift probably caused by almost complete first-pass metabolism. Therapeutic effects of betahistine result from an enhancement of histamine neuron activity induced by inverse agonism at H(3) autoreceptors [2].
){kind=link}